Celgene - Global Share Gains Continue + Pipeline Potential
Robust performance on all commercial metrics – global share and duration gains, continued expansion of market access through approvals and reimbursements in the US and international market, and noteworthy operating efficiency places Celgene (CELG) as a long term growth opportunity in the Biotech sector. Total revenue growth was up 38% (YoY, #6% QoQ) and product sales grew by 40% (YoY, #8% QoQ) due to robust uptake of Revlimid (L, MM, MDS). CELG has revised its FY11 guidance positively and expects Non-GAAP total revenue to increase… For more details on other products, pipeline and upcoming catalysts, please read our report released on 5th August, 2011, titled – “Global Share Gains Continue + Pipeline Potential”.
COMPANIES MENTIONED
Celgene
Celgene
